Skip to main content

Table 1 Study population characteristics

From: Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC

Characteristic (%)

ATG (N = 363)

CD34 (N = 162)

p

Patient age, median (range)

46 (19–77)

58 (20–73)

< 0.001

Year of transplant

2012 (2005–2015)

2011 (2005–2015)

Patient gender

 Male

200 (55%)

90 (56%)

0.92

 Female

163 (45%)

72 (44%)

Female donor to male patient

65 (18%)

37 (23%)

0.19

Karnofsky performance scale

 ≥ 90%

258 (76%)

100 (63%)

0.003

 < 90%

83 (24%)

59 (37%)

 unknown

22

3

CMV serologic status

 Seronegative donor-recipient pair

114 (32%)

49 (33%)

0.4

Time from diagnosis to transplant, months (range)

4.9 (1.9–14.3)

4.3 (1.7–11.4)

0.001

Cytogenetic

 Intermediate

259 (71%)

112 (69%)

0.61

 Poor

104 (29%)

50 (31%)

Donor

 Matched related donor

118 (33%)

73 (45%)

0.006

 Unrelated donor

245 (67%)

89 (55%)

Conditioning regimen

 Busulfan + fludarabine

173 (48%)

0

< 0.0001

 Busulfan + cycloclophosphamide

129 (36%)

0

 TBI + cyclophosphamide

61 (17%)

0

 Busulafan + fludarabine + melphalan

0

107 (66%)

 TBI + cycloclophosphamide + thiotepa

0

45 (28%)

 TBI + fludarabine + thiotepa

0

10 (6%)

GVHD prophylaxis

 CsA

62 (17%)

 CsA + MMF

210 (58%)

 CsA + MTX

65* (18%)

 Tacrolimus + sirolimus

10 (3%)

 PT Cy

5 (1%)

 Others

11 (3%)

Antithymocyte globuline

 Thymoglobulin (median dose, mg/kg; range)

233 (5; 5–7.5)

143 (5; 2–5)

 

 Grafalon, (median dose, mg/kg; range)

130 (35; 8–60)

0

 

 Equine ATG, (median dose, mg/kg; range)

0

12 (30; 15–30)

Cells doses

 CD34+ cells, × 106/kg (range)

6.13 (1.64–21.2)

8.18 (1.1–31.2)

< 0.0001

 CD 3+ cells, × 106/kg (range)

213 (1.13–643)

0.002 (0–0.063)

< 0.0001

  1. Abbreviations: TBI total body irradiation, GVHD graft versus host disease, CsA ciclosporine A, MMF mycophenolate mofetil, PT Cy post-transplant cyclophosphamide, NA not available
  2. *In two patients, CsA have been substituted by tacrolimus